Fotivda

Active Ingredient(s): Tivozanib Hydrochloride
FDA Approved: * March 10, 2021
Pharm Company: * AVEO PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Fotivda Overview

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).[1] It is an oral VEGF receptor tyrosine kinase inhibitor.[1] It was discovered by Kyowa Kirin and developed by AVEO Pharmaceuticals.[3] The most common side effects include fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.[1]...

Read more Fotivda Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tivozanib

Recent Fotivda Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tivozanib Hydrochloride
  • Capsule: 0.89mg, 1.34mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fotivda: (2 results)

Sorted by National Drug Code
  • 45629-089 Fotivda .89 mg Oral Capsule by Aveo Pharmaceuticals, Inc.
  • 45629-134 Fotivda 1.34 mg Oral Capsule by Aveo Pharmaceuticals, Inc.

Other drugs which contain Tivozanib Hydrochloride or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 19 June 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA